← Filings of VRTX

Tables in the 10-Q of VERTEX PHARMACEUTICALS INC / MA

43 tables with numbers, filed Aug 4, 2026. Each one downloads as an Excel file or a CSV (numbers are stored as numbers), with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

		Page
Part I. Financial Information
Item 1.	Financial Statements (unaudited)	2
	Condensed Consolidated Statements of Income	2
	Condensed Consolidated Statements of Comprehensive Income	3
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Shareholders' Equity	5
	Condensed Consolidated Statements of Cash Flows	6

	Three Months Ended June 30,	Six Months Ended June 30,
	2026	2025	2026	2025
Revenues:
Product revenues, net	$3,333.9	$2,944.0	$6,320.8	$5,704.2
Other revenues	—	20.7	—	30.7
Total revenues	3,333.9	2,964.7	6,320.8	5,734.9
Costs and expenses:
Cost of sales	489.2	407.5	882.0	770.5

	June 30, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$6,143.5	$5,084.8
Marketable securities	1,708.9	1,523.3
Accounts receivable, net	2,134.3	2,052.8
Inventories	1,765.1	1,686.8
Prepaid expenses and other current assets	791.9	853.3

	Three Months Ended
	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Total Shareholders’ Equity
	Shares	Amount
Balance at March 31, 2025	257.0	$2.6	$6,172.5	$68.1	$10,253.1	$16,496.3
Other comprehensive loss, net of tax	—	—	—	(169.2)	—	(169.2)
Net income	—	—	—	—	1,032.9	1,032.9
Repurchases of common stock	(0.9)	—	(397.3)	—	—	(397.3)
Common stock withheld for employee tax obligations	—	—	(5.9)	—	—	(5.9)

	As of June 30, 2026	As of December 31, 2025
		Fair Value Hierarchy		Fair Value Hierarchy
	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3
	(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents	$2,656.9	$1,351.5	$1,305.4	$—	$2,779.1	$1,770.7	$1,008.4	$—
Marketable securities:
Corporate equity securities	11.9	11.9	—	—	16.6	16.6	—	—

	Six Months Ended June 30, 2026
	(in millions)
Balance at December 31, 2025	$79.0
Increase in fair value of contingent payments	0.6
Balance at June 30, 2026	$79.6

	As of June 30, 2026	As of December 31, 2025
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
	(in millions)
Cash equivalents	$2,656.9	$—	$—	$2,656.9	$2,779.1	$—	$—	$2,779.1
Marketable securities:
U.S. Treasury securities	1,668.0	0.4	(8.0)	1,660.4	1,852.9	12.1	(0.1)	1,864.9
U.S. government agency securities	191.0	0.2	(0.4)	190.8	261.2	1.2	—	262.4
Asset-backed securities	1,236.1	1.2	(3.8)	1,233.5	1,351.1	6.0	(0.1)	1,357.0

		Unrealized Holding Gains (Losses), Net of Tax
	Foreign Currency Translation Adjustment	On Available-For-Sale Debt Securities	On Foreign Currency Forward Contracts	Total
	(in millions)
Balance at December 31, 2025	$37.2	$34.0	$(87.1)	$(15.9)
Other comprehensive (loss) income before reclassifications	(11.6)	(49.1)	96.7	36.0
Amounts reclassified from accumulated other comprehensive income (loss)	—	0.5	27.9	28.4
Net current period other comprehensive (loss) income	(11.6)	(48.6)	124.6	64.4
Balance at June 30, 2026	$25.6	$(14.6)	$37.5	$48.5

	As of June 30, 2026	As of December 31, 2025
Foreign Currency	(in millions)
Euro	$3,520.1	$4,677.9
Canadian dollar	371.7	516.1
British pound sterling	351.6	492.6
Australian dollar	278.0	267.5
Swiss franc	91.2	126.0
Total foreign currency forward contracts	$4,612.6	$6,080.1

As of June 30, 2026
Assets	Liabilities
Classification	Fair Value	Classification	Fair Value
(in millions)
Prepaid expenses and other current assets	$60.8	Other current liabilities	$(35.2)
Other assets	39.9	Other long-term liabilities	(17.4)
Total assets	$100.7	Total liabilities	$(52.6)

	Six Months Ended June 30,
	2026	2025
Cash flows from operating activities:
Net income	$2,131.2	$1,679.2
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	336.6	333.4
Depreciation and amortization expense	112.4	100.1
Intangible asset impairment charge	—	379.0

	Three Months Ended June 30,	Six Months Ended June 30,
	2026	2025	2026	2025
	(in millions, except per share amounts)
Net income	$1,099.8	$1,032.9	$2,131.2	$1,679.2
Basic weighted-average common shares outstanding	253.7	256.7	253.9	256.8
Effect of potentially dilutive securities:
Restricted stock units (including performance-based restricted stock units (“PSUs”))	0.9	1.3	1.2	1.4
Stock options	0.6	0.9	0.6	1.0

	As of June 30, 2026	As of December 31, 2025
	(in millions)
Matures within one year	$1,697.0	$1,506.7
Matures after one year through five years	5,689.5	5,595.8
Matures after five years	99.6	116.5
Total	$7,486.1	$7,219.0

	As of June 30, 2026	As of December 31, 2025
	(in millions)
Raw materials	$233.0	$259.8
Work-in-process	1,253.9	1,196.9
Finished goods	278.2	230.1
Total	$1,765.1	$1,686.8

	As of June 30, 2026
	Gross Amounts Recognized	Gross Amounts Offset	Gross Amounts Presented	Gross Amounts Not Offset	Legal Offset
Foreign currency forward contracts	(in millions)
Total assets	$100.7	$—	$100.7	$(52.6)	$48.1
Total liabilities	(52.6)	—	(52.6)	52.6	—

		As of June 30, 2026	As of December 31, 2025
	Estimated Useful Lives	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
		(in millions, except useful lives)
In-process research and development	Indefinite	$224.6	$—	$224.6	$224.6	$—	$224.6
Finite-lived intangible assets - marketed products	10 to 12 years	238.0	(52.2)	185.8	238.0	(42.1)	195.9
Finite-lived intangible assets - assembled workforce	3 years	7.7	(5.3)	2.4	7.7	(4.0)	3.7
Total other intangible assets, net		$470.3	$(57.5)	$412.8	$470.3	$(46.1)	$424.2

Total Revenues	In the second quarter of 2026, our total revenues increased to $3.3 billion as compared to $3.0 billion in the second quarter of 2025, primarily due to continued performance of our CF therapies and growth from diversification into additional disease areas.
Cost of Sales	Our cost of sales as a percentage of our net product revenues increased to 14.7% in the second quarter of 2026 as compared to 13.8% in the second quarter of 2025, as a result of changes in product mix, partially offset by a lower blended royalty rate for our CF medicines.
Total R&D, AIPR&D and SG&A Expenses	Our total research and development (“R&D”), acquired in-process research and development expenses (“AIPR&D”) and selling, general and administrative (“SG&A”) expenses increased to $1.6 billion in the second quarter of 2026 as compared to $1.4 billion in the second quarter of 2025, primarily due to increased investment to commercialize our new products.
Cash	Our total cash, cash equivalents and marketable securities increased to $13.6 billion as of June 30, 2026 as compared to $12.3 billion as of December 31, 2025 primarily due to cash flows provided by our operating activities, partially offset by repurchases of our common stock.

	As of June 30, 2026	As of December 31, 2025	Change
	(in millions, except percentages)
Cash, cash equivalents and marketable securities:
Cash and cash equivalents	$6,143.5	$5,084.8
Marketable securities	1,708.9	1,523.3
Long-term marketable securities	5,789.1	5,712.3
Total cash, cash equivalents and marketable securities	$13,641.5	$12,320.4	11%
Working Capital:

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)	Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
April 1, 2026 to April 30, 2026	375,000	$436.21	375,000	$2,873,410,086
May 1, 2026 to May 31, 2026	366,652	$434.50	366,652	$2,714,101,470
June 1, 2026 to June 30, 2026	292,000	$452.37	292,000	$2,582,008,580
Total	1,033,652	$440.17	1,033,652	$2,582,008,580

Exhibit Number	Exhibit Description
2.1^	Agreement and Plan of Merger by and among Crinetics Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, and Clark Merger Sub, Inc. dated July 6, 2026 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission by Crinetics Pharmaceuticals, Inc. on July 6, 2026).
10.1	Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan dated (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 filed with the Securities and Exchange Commission by Vertex Pharmaceuticals Incorporated on May 13, 2026).*
10.2	Form of Restricted Stock Unit Agreement under the 2026 Stock and Option Plan.*
10.3	Form of Restricted Stock Unit Agreement (with Performance Conditions) under the 2026 Stock and Option Plan.*
10.4	Form of Restricted Stock Unit Agreement (for Non-Employee Directors) under the 2026 Stock and Option Plan.*
10.5	Form of Option Agreement (for Non-Employee Directors) under the 2026 Stock and Option Plan.*
10.6	Non-Employee Director Deferred Compensation Plan.*

Tables in the 10-Q of VERTEX PHARMACEUTICALS INC / MA

Table 1 after “TABLE OF CONTENTS”

Table 2 after “(unaudited; in millions, except per share amounts)”

Table 3 after “(unaudited; in millions)”

Table 4 after “(unaudited; in millions, except share and per share data)”

Table 5 after “(unaudited; in millions)”

Table 6 after “(unaudited; in millions)”

Table 7 after “for CRISPR’s share of CRISPR JDCA activities were as follows:”

Table 8 after “per common share for the periods ended:”

Table 9 after “:”

Table 10 after “:”

Table 11 after “The following table represents a rollforward of the fair value of our contingent consideration liabilities:”

Table 12 after “below:”

Table 13 after “Amounts in the table above at fair value were classified on our condensed consolidated balance sheets as follows:”

Table 14 after “Marketable available-for-sale debt securities by contractual maturity were as follows:”

Table 15 after “period were as follows:”

Table 16 after “component:”

Table 17 after “contracts designated as cash flow hedges under U.S. GAAP:”

Table 18 after “:”

Table 19 after “flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:”

Table 20 after “flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:”

Table 21 after “designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:”

Table 22 after “designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:”

Table 23 after “following:”

Table 24 after ““Other intangible assets, net” consisted of the following:”

Table 25 after “expense:”

Table 26 after “income taxes.”

Table 27 after “consisted of the following:”

Table 28 after “consisted of the following:”

Table 29 after “Significant segment expenses are set forth in the following table:”

Table 30 after “consolidated statements of cash flows consisted of the following:”

Table 31 after “Financial Highlights”

Table 32 after “Total Revenues”

Table 33 after “Our total revenues from the U.S. and from ex-U.S. markets were as follows:”

Table 34 after “Operating Costs and Expenses”

Table 35 after “Research and Development Expenses”

Table 36 after “Research Expenses”

Table 37 after “Development Expenses”

Table 38 after “Acquired In-Process Research and Development Expenses”

Table 39 after “Selling, General and Administrative Expenses”

Table 40 after “:”

Table 41 after “Cash Flows”

Table 42 after “Table of Contents”

Table 43 after “Exhibits”